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Abstract
Background: People who inject drugs (PWID) are at an increased risk of wound botulism, a potentially fatal acute
paralytic illness. During the first 6 months of 2015, a large outbreak of wound botulism was confirmed among
PWID in Scotland, which resulted in the largest outbreak in Europe to date.
Methods: A multidisciplinary Incident Management Team (IMT) was convened to conduct an outbreak investigation,
which consisted of enhanced surveillance of cases in order to characterise risk factors and identify potential sources of
infection.
Results: Between the 24th of December 2014 and the 30th of May 2015, a total of 40 cases were reported across six
regions in Scotland. The majority of the cases were male, over 30 and residents in Glasgow. All epidemiological
evidence suggested a contaminated batch of heroin or cutting agent as the source of the outbreak. There are
significant challenges associated with managing an outbreak among PWID, given their vulnerability and complex
addiction needs. Thus, a pragmatic harm reduction approach was adopted which focused on reducing the risk of
infection for those who continued to inject and limited consequences for those who got infected.
Conclusions: The management of this outbreak highlighted the importance and need for pragmatic harm reduction
interventions which support the addiction needs of PWID during an outbreak of spore-forming bacteria. Given the
scale of this outbreak, the experimental learning gained during this and similar outbreaks involving spore-forming
bacteria in the UK was collated into national guidance to improve the management and investigation of future
outbreaks among PWID.
Keywords: Wound botulism, People who inject drugs, Outbreak investigation, Harm reduction
Background
Wound botulism is a serious and potentially fatal acute
paralytic illness caused by a highly potent neurotoxin
produced by Clostridium botulinum [1]. Spores of C.
botulinum are found in soil and can be introduced into
illicit drugs such as heroin at any stage from point of
production to use [1, 2]. People who inject drugs
(PWID) are at an increased risk of infection, particularly
if they inject under the skin (“skin popping”) or into
muscle (“muscle popping”) either deliberately or as a re-
sult of a “missed hit” (i.e. someone missing a vein when
trying to inject intravenously). The necrotic devitalised
tissue at the site of injection provides an ideal anaerobic
environment for C. botulinum spores to germinate,
multiply and produce toxin which then gets absorbed
into the systemic circulation causing a neuroparalytic
syndrome [3–7].
Although wound botulism in PWID have been noted
in numerous countries across the world [4, 8–12], the
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UK appears to be disproportionately affected with a
number of outbreaks of wound botulism and other
spore-forming bacteria such as Clostridium novyi, Bacil-
lus anthracis and Clostridium tetani [5, 13–17]. Between
2000 and 2014, there were a total of 170 reported cases
of wound botulism among PWID in the UK. In 2015
alone, there were 47 reported cases, the largest outbreak
of wound botulism seen among PWID in Europe, which
was focused on Glasgow, Scotland [18]. Prior to the out-
break, the last probable (though unconfirmed) case in
Scotland was reported in 2009.
The outbreak began on Wednesday the 24th of
December 2014, when NHS Greater Glasgow and Clyde
(NHS GGC) health board Public Health Protection Unit
(PHPU) were notified that a Glasgow resident in their
thirties with a history of injecting drug use had been ad-
mitted to a hospital in Glasgow with neurological symp-
toms suggestive of botulism. Exactly 1 week later, NHS
GGC were notified of a further suspected case, also in
their thirties with a history of injecting drug use. The
identification of two probable cases of wound botulism
with a history of injecting drugs in a 1-week period sug-
gested the contamination of a batch of heroin and/or
cutting agent. In the ensuing weeks, further cases of sus-
pected wound botulism were reported across six NHS
health boards in Scotland. This report describes the
epidemiological characteristics of what became the lar-
gest outbreak of wound botulism among PWID seen in
Europe thus far [18], and the pragmatic harm reduction
approach taken to limit morbidity and mortality associ-
ated with the infection during the outbreak. This manu-
script aims to raise awareness of wound botulism and
the importance and the need of harm reduction policies
for the management of outbreaks among PWID.
Methods
Outbreak response
Initially, the outbreak was managed by an Incident Man-
agement Team (IMT) based at NHS GGC. As the num-
ber of NHS health boards affected increased, a national
IMT was convened and led by Health Protection
Scotland (HPS). The multidisciplinary IMT consisted of
representatives from NHS health boards, police (Police
Scotland), non-governmental organisations (Scottish
Drugs Forum), Public Health England (PHE), reference
laboratories (Gastrointestinal Bacteria Reference Unit
(GBRU)) and the Scottish Government.
Epidemiologic investigation
The IMT adapted the European Centre for Disease Con-
trol (ECDC) case definition of botulism for the outbreak,
which included clinical, epidemiological and microbio-
logical criteria (available from: http://eur-lex.europa.eu/
legal-content/EN/TXT/PDF/?uri=CELEX:32012D0506&
qid=1428573336660&from=EN#page=7) (Table 1). The
case definition was categorised by the degree of certainty
regarding the diagnosis as:
Probable case—a high clinical suspicion and
epidemiological evidence consistent with botulism
Confirmed case—clinical, epidemiological and
microbiological evidence consistent with botulism
Additionally, a “possible” case classification was used,
when dealing with the initial report of suspected cases
that merited further investigation. This provisional clas-
sification was given following review of the case by the
Consultant Microbiologist of the GBRU and the treating
physician. Cases were classified as “probable” or “con-
firmed” when further information became available.
Botulism is legally notifiable under the Public Health
Act (Scotland) 2008 (available from: http://www.gov.scot
/Resource/0039/00398162.pdf ). For all cases identified,
information on personal and medical details, source of
drugs and drug use prior to the onset of illness, was
collected using an established national enhanced surveil-
lance form (available from: https://www.gov.uk/govern-
ment/uploads/system/uploads/attachment_data/file/5774
02/PWID_Botulism_Questionnaire_2006.1.6_14_Decem-
ber_2016.pdf ). Copies of the completed form were sent
to HPS and collated on a copy of an Access database uti-
lised by PHE for the UK surveillance of botulism associ-
ated with PWID.
Laboratory investigations
Microbiological confirmation of a clinical diagnosis of
botulism requires the timely collection of appropriate
clinical samples such as serum and tissue before admin-
istration of anti-toxin and commencement of antibiotics
respectively. The early collection of samples following
onset of symptoms maximises the opportunity for diag-
nosis. Confirmation was undertaken by either detection
of toxin in serum by mouse bioassay (MBA), or by isola-
tion of Clostridium botulinum from pus or wound tissue
by culture and PCR detection of neurotoxin genes. Typ-
ing of C. botulinum isolates was performed by fAFLP as
described previously [19].
Police investigation
The public health investigation of this outbreak was sup-
ported by a parallel criminal investigation undertaken by
Police Scotland. The objective of their investigation was
to determine the source of the suspected contaminated
heroin with a view to removing or reducing the amount
of contaminated drugs in circulation, thereby maximis-
ing the safety of all individuals involved in the outbreak.
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Results
Descriptive epidemiology
A total of 47 individuals presented to hospital, between
the 21st of December 2014 and the 29th of May 2015,
with symptoms indicative of botulism. Seventeen of
these were confirmed microbiologically and 23 cases
were classed as probable (Fig. 1). Two cases were classi-
fied as (and remain) possible, with the remaining five
cases discounted. The following analysis describes the 40
confirmed/probable cases only.
The majority of cases (98%) presented with classical
symptoms of oculomotor and bulbar palsy but very few
with descending limb weakness; over half (58%) were
ventilated for respiratory paralysis although most did not
require long-term support. All cases were promptly
treated with antitoxin, 50% underwent wound debride-
ment and all received antibiotics. There were four
deaths; botulism was a contributory cause in two cases
(case fatality rate (CFR) = 5%) [20].
Most of the cases were male (68%). The mean age
among males and females was 44 and 38 years, respect-
ively. All confirmed/probable cases were aged between
24 and 56 years old. The majority of cases were aged be-
tween 36 and 45 years old [20].
Cases were spread across the central belt of Scotland,
with the majority residing in NHS GGC (63%), followed
by NHS Lanarkshire (18%), NHS Forth Valley (15%),
NHS Fife (2.5%) and NHS Ayrshire & Arran (2.5%) [20].
Risk information
Detailed information on the history of drugs taken
and route of administration was available for 34 of
the 40 confirmed/probable cases. Where information
was available, all cases reported using heroin, either
alone (52%) or in combination with another drug. Of
the 29 cases who reported their length of drug use,
50% had used drugs for over 10 years. Most of the
cases (62%) reported using a combination of routes
for administering their drugs in the month prior to
illness (intravenous, skin/muscle popping, smoking/
snorting) [20].
Microbiology
A total of 17/40 (43%) cases were confirmed micro-
biologically: Clostridium botulinum type B was de-
tected by PCR in wound pus or tissue from 13
patients, and botulism neurotoxin type B was de-
tected in serum of 3 patients while in a fourth patient
toxin detection was confirmed but not typed. For 2
other cases, the MBA result was unconfirmed due to
insufficient serum to perform the neutralisation test.
Molecular typing of the organism isolated from 11
patients gave an indistinguishable fAFLP profile indi-
cating a common source of infection. All heroin
seized by Police Scotland tested negative for Clostrid-
ium botulinum.
Table 1 Clostridium botulinum outbreak case definition
Clinical Any person with at least one of bilateral cranial nerve impairment (e.g. diplopia, blurred vision, dysphagia, bulbar
weakness) or peripheral symmetric paralysis.
Epidemiological Use of illicit drugs by any route within the 2 weeks prior to onset of symptoms.
Microbiological Isolation of Clostridium botulinum from infected wound and/or detection of botulinum toxin in a clinical specimen.
Fig. 1 Date of hospital admission and case definitions of wound botulism infections among people who inject drugs, 21st of December 2014 to
29th of May 2015. N = 40
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Risk management and risk communication
In the absence of intelligence on which (or how
many) batches of heroin in circulation were poten-
tially contaminated, all PWID were considered to be
at risk of exposure and infection. Information from
the initial cases on the source of their drugs used
prior to symptoms suggested a focus on heroin ob-
tained in or sourced via Glasgow city. Therefore, in-
terventions to manage the incident were targeted in
GGC and surrounding NHS boards.
The IMT recognised that it was not a realistic expect-
ation to be able to remove all contaminated drugs or
cutting agents from the market, or to eliminate drug use
among the susceptible cohort. The illicit consumption
and supply of drugs mean that there is little intelligence
on the source of contaminated drugs. Thus, a pragmatic
harm reduction approach was adopted (Table 2). This
approach, while recognising that the only way to elimin-
ate risk of infection was to stop using drugs, also de-
ployed interventions to reduce risk as far as possible for
those who continued to inject and for those who were
infected, reduce the risk of progression to serious illness.
To raise awareness of the outbreak, communicate safer
injection practices (for example, do not inject into the
muscle or skin and promote smoking rather than inject-
ing) and encourage early recognition of signs and symp-
toms, a postcard was created and made available to
those at risk via all frontline and addiction services
(mainly IEP services) across the NHS board areas in-
volved (Fig. 2). The postcard was intended as an instru-
ment for IEP staff to engage PWID in discussion, to
raise awareness of botulism and safer injecting prac-
tices which reduce the risk of botulism. In addition,
and in recognition that these services were key to
identifying individuals at risk and filtering harm re-
duction messages, an information booklet, “Wound
botulism and drug use: What workers need to know”
composed by the Scottish Drug Forum (SDF) (avail-
able from: http://www.sdf.org.uk/wp-content/uploads/
2017/03/Botulism_Booklet.pdf ), was developed and
distributed to frontline staff with an opportunity to
reinforce the learning through a workshop delivered
by SDF. Furthermore, this ensured that staff were
equipped to answer questions from PWID about the
outbreak.
The IMT released three media statements and com-
municated regularly through the duration of the out-
break with GPs, hospitals and services for drug users to
raise awareness of signs and symptoms, diagnostic pro-
cedures and how to obtain botulism antitoxin.
Discussion
A multi NHS board outbreak of Clostridium botulinum
among PWID in Scotland resulted in 40 cases of botu-
lism, representing the largest outbreak of wound botu-
lism among PWID in Europe to date [18]. The
epidemiology of the cases (predominantly male and over
30 years old) is representative of the PWID population
in GGC [18]. Clostridium botulinum spores were not
detected in samples of heroin which were obtained by
Police Scotland, reflecting experiences from other out-
breaks [8, 21, 22]. However, all epidemiological evidence
suggested a contaminated batch of heroin or cutting
agent as the source of the outbreak [20]. Given that the
heroin in circulation in the UK is predominantly sup-
plied through trafficking routes from Afghanistan, it is
likely that a contamination event at some point higher
up the distribution chain is the source of infections re-
ported in the UK and Europe [2, 17].
There are significant challenges associated with man-
aging an outbreak of botulism among PWID. The only
way to completely eliminate the risk of infection is to re-
move all contaminated drugs from the market, or to
eliminate drug use among the susceptible population,
neither of which are a realistic expectation. The recom-
mendations and interventions to minimise the risk to
PWID deployed during this outbreak were by necessity
pragmatic, and focused on reducing the risk of infection
for those who continued to inject drugs, and limiting the
consequences for those who became infected. The over-
all strategy to manage the outbreak was predicated on
augmenting the comprehensive harm reduction services
currently deployed in Scotland [23, 24], with enhanced
interventions aimed at specifically reducing risk of ex-
posure, e.g. the provision of foil to encourage smoking
as an alternative to injecting, reviewing and expanding
access to injecting equipment provision (IEP) and opiate
substitution therapy (OST) services. While there is a
lack of evidence that increasing injecting equipment
provision reduces risk from bacterial infection, research
Table 2 Hierarchy of objectives and advice/interventions
Objective Advice/intervention
Eliminate risk of infection • Advice on how to reduce or eliminate drug use altogether
• Information on access to opiate substitution therapy services
Reduce risk of infection • Advice on switching to safer route of drug use
• Provision of foil to encourage smoking as an alternative to injecting
• Advice on safer injecting behaviour (ensuring they inject into a vein)
Reduce risk of severity • Education and awareness raising of the signs and symptoms of illness and where to seek help
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suggests that it can attract and retain PWID in services
[25] and therefore provide a vital window of opportunity
to raise awareness of the outbreak and to filter harm re-
duction messages to those at ongoing risk.
The communication strategy employed during the out-
break had two strands. The first strand involved com-
municating with health professionals. Many frontline
healthcare workers (HCW) have limited practical experi-
ence of identifying cases of botulism, especially as signs
of drug overdose or effects of multiple drugs can mask
early signs of botulism [7]. As early diagnosis and treat-
ment improves outcome and reduces risk of death [26–
28], the IMT alerted frontline healthcare professionals to
the presenting symptoms and provided guidance on the
clinical management of botulism including how to ob-
tain botulism antitoxin. The impact of ensuring aware-
ness of the outbreak and quicker treatment initiation
was reflected in shorter hospital stays as the outbreak
continued and the majority of cases making a full recov-
ery [29]. All information resources used during the out-
break were shared widely across Scotland. In addition,
given the role Glasgow plays in the distribution of drugs
throughout Scotland and the potential for contaminated
heroin to be re-distributed across the country or else-
where in the Europe, all resources developed to manage
the incident were shared with colleagues across the
country. Furthermore, an alert notice was posted
through the European Union’s (EU) Early Warning and
Response System (EWRS) on 2 January 2015.
The second strand included communicating with those
at risk. Experience from previous outbreaks of spore-
forming bacteria in PWID suggested that there was lim-
ited benefit of using conventional press or mass media as
outlets for awareness-raising activities. Information was
Fig. 2 Awareness-raising postcard distributed to people who inject drugs during the outbreak
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therefore targeted at those at risk through the develop-
ment of a “postcard” early in the outbreak which con-
tained information on risk reduction measures and signs
and symptoms of infection (Fig. 2). Given the sudden on-
set of the outbreak and the need to respond quickly, peers
were not involved in the development of the postcard but
reviewed the postcard after it had been created. The im-
pact of the postcard was evaluated via the Needle Ex-
change Surveillance Initiative [30, 31] and qualitative
interviews with persons who attended NHS GGC IEP
services and had injected in the previous 6 months. The
results suggested that the postcard may have improved
awareness of the outbreak, the signs and symptoms of
botulism and encouraged injecting behaviour change to
reduce the risks of exposure, particularly when it was used
as a prompt by frontline service providers for a focused
discussion. The qualitative arm of the study revealed that
the injection advice from the postcard which was
most effective was to “ensure that they inject into a
vein”. Research suggests that PWID are grateful of
pragmatic injecting advice [32] which recognises that
PWID will continue to inject, despite risk of infec-
tion. Further research is needed, however, to establish
the best mechanism for distribution and engagement
with PWID, as many remained unaware of the risk
they face during an outbreak [31].
Given the special role that frontline HCWs and IEP staff
have as an access point to reach PWID at risk, their views
and experiences of the response and communication of
the outbreak should be explored to identify barriers and
ensure best practice in future outbreaks. Improving com-
munication and trust between these service providers and
peers may improve the effectiveness of future outbreak
alerts among PWID [33]. Research has highlighted that
communication from peer-based social networks are an
important source of information [34] and should be uti-
lised more often. Thus, peer-delivered communication
strategies and the involvement of peers and frontline staff
in the development of interventions such as the postcard
could be key to overcoming the communication barriers
experienced during this outbreak.
Officials in Glasgow have proposed the opening of a
drug consumption room (DCR) and the establishment of
a heroin-assisted treatment (HAT) service [35], in re-
sponse to past outbreaks of spore-forming bacteria [13–
15], high incidence of drug-related deaths [36] and an on-
going HIV outbreak [37]. The establishment of both these
services may be an effective method of minimising the risk
of another outbreak of spore-forming bacteria. HAT ser-
vices would usually have stringent inclusion criteria [38];
however, these criteria could be relaxed during a severe
outbreak. Furthermore, a DCR could promote safer inject-
ing practices [39], potentially reducing the probability of
soft tissue infections and therefore reducing the risk of
wound botulism. Additionally, the presence of HCW in
the DCR may help the detection and early recognition of
spore-forming bacterial infections.
Conclusion
The management of this outbreak, the largest to date in
Europe [18], highlights the importance and need for
greater recognition of a pragmatic harm reduction
approach that supports the addiction needs of those
vulnerable to infection during an outbreak of
spore-forming bacteria. The approach adopted took on-
board significant experiential learning that had been
gained from similar outbreaks of spore-forming bacterial
infection in the UK since 2000 [5, 13–17]. Alongside ex-
pert knowledge and published evidence where available,
the experimental learning has been collated into a single
guidance document published by the Scottish Health
Protection Network “Guidelines for the public health
management of tetanus, botulism or anthrax among
people who use drugs” [40], to facilitate an efficient and
effective response to future outbreaks. The response to
this outbreak could have been further improved through
deeper collaborations with peer and frontline staff, par-
ticularly by considering the use of peer-based social net-
works to filter harm reduction communications.
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